We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01252641
Recruitment Status : Completed
First Posted : December 3, 2010
Last Update Posted : September 20, 2019
Information provided by (Responsible Party):
Sangamo Therapeutics

Brief Summary:

This research study is being carried out to study a new way to possibly treat human immunodeficiency virus (HIV). The agent is called SB-728-T which are CD4+ T-cells obtained from an individual that are genetically modified at the CCR5 gene by Zinc Finger Nucleases. The CCR5 gene is required for certain types of HIV to enter into and infect T-cells. T cells are one of the white blood cells used by the body to fight HIV. The most important of these are called "CD4+ T-cells"

Some people are born without the CCR5 gene on their T-Cells. These people remain healthy and are resistant to infection with HIV. Other people have a low number of CCR5 genes on their T-cells and their HIV disease is less severe and is slower to cause disease (AIDS).

The purpose of this research study is to find out whether SB-728-T is safe to give to humans and find out how this affects HIV.

Condition or disease Intervention/treatment Phase
HIV HIV Infection Biological: SB-728-T Phase 1 Phase 2

Detailed Description:

Laboratory studies have shown that when CD4+ T-cells are modified with Zinc Finger Nucleases SB-728, HIV is prevented from killing the CD4+ T-cells. On the basis of these laboratory results, there is the potential that this may work in humans infected with HIV and improve their immune system by allowing their CD4+ T-cells to survive longer.

The new treatment to be studied will involve removing white blood cells from the blood that contain CD4+ T-cells. The extracted CD4+ T-cells are then genetically modified by the Zinc finger Nucleases to be resistant to infection by removing the CCR5 gene from the surface of the CD4+ T-cell where HIV enters the cell. Additional genetically modified cells are manufactured and then re-infused back into the individual. Researchers hope that these genetically modified cells will be resistant to infection by HIV and will be able to reproduce additional resistant CD4+ T-cells in your body.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2, Open Label, Single Infusion Study of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases (SB-728-T) in HIV Infected Subjects
Study Start Date : November 2010
Actual Primary Completion Date : December 2014
Actual Study Completion Date : May 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: SB-728-T
Subjects will receive one intravenous infusion of SB-728-T
Biological: SB-728-T
Each infusion will be 5-30 billion modified CD4+ T-cells

Primary Outcome Measures :
  1. Evaluate the safety and tolerability of SB-728-T cells infusion in HIV-1 positive subjects [ Time Frame: 12 months ]
    Evaluate the safety and tolerability of a single infusion of 5-30 billion SB-728-T cells in HIV-1 positive subjects

Secondary Outcome Measures :
  1. Evaluate persistence of HIV as measured by HIV-1 RNA, [ Time Frame: 12 months ]
  2. Change in CD4+ T-cell count [ Time Frame: 12 months ]
  3. Persistence of SB-728-T in the peripheral blood [ Time Frame: 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Documented HIV infection
  • CD4+ T-cell count >500 cell per millimeter cubed (cells/mm3)
  • CD4+ T-cell nadir of >400 cells/mm3
  • HIV viral load >1,000 copies per milliliter (mL)

Exclusion Criteria:

  • Any viral hepatitis
  • Acute HIV infection
  • HIV viral load >1,000,000 copies/mL
  • Active or recent (prior 6 months) AIDS defining complication
  • Any HIV medications within the past 12 weeks
  • Cancer or malignancy that has not been in remission for at least 5 years with the exception of successfully treated basal cell carcinoma of the skin
  • Current diagnosis of NYHA grade 3 or 4 congestive heart failure or uncontrolled angina or arrhythmias
  • History of bleeding problems
  • Use of chronic steroids in past 30 days
  • Pregnant or breast feeding
  • Active drug or alcohol abuse
  • Serious illness in past 30 days
  • Currently participating in another clinical trail or any prior gene therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01252641

Layout table for location information
United States, California
Los Angeles, California, United States, 90035
Orange Coast Medical Group
Newport Beach, California, United States, 92663
Quest Clinical Research
San Francisco, California, United States, 94115
United States, Florida
Orlando Immunology Center
Orlando, Florida, United States, 32803
Sponsors and Collaborators
Sangamo Therapeutics
Layout table for investigator information
Study Director: Winson Tang, M.D. Sangamo BioSciences, Inc.
Layout table for additonal information
Responsible Party: Sangamo Therapeutics
ClinicalTrials.gov Identifier: NCT01252641    
Other Study ID Numbers: SB-728-1002
First Posted: December 3, 2010    Key Record Dates
Last Update Posted: September 20, 2019
Last Verified: September 2019
Keywords provided by Sangamo Therapeutics:
Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
Blood-Borne Infections
Communicable Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Genital Diseases
Urogenital Diseases
Immunologic Deficiency Syndromes
Immune System Diseases